User menu

A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck

Bibliographic reference Machiels, Jean-Pascal ; Specenier, P ; Krauß, J ; Dietz, A ; Kaminsky, M-C ; et. al. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. In: Cancer Chemotherapy and Pharmacology, Vol. 76, no.1, p. 13-20 (2015)
Permanent URL
  1. Vermorken Jan B., Mesia Ricard, Rivera Fernando, Remenar Eva, Kawecki Andrzej, Rottey Sylvie, Erfan Jozsef, Zabolotnyy Dmytro, Kienzer Heinz-Roland, Cupissol Didier, Peyrade Frederic, Benasso Marco, Vynnychenko Ihor, De Raucourt Dominique, Bokemeyer Carsten, Schueler Armin, Amellal Nadia, Hitt Ricardo, Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer, 10.1056/nejmoa0802656
  2. Vermorken Jan B, Stöhlmacher-Williams Jan, Davidenko Irina, Licitra Lisa, Winquist Eric, Villanueva Cristian, Foa Paolo, Rottey Sylvie, Skladowski Krzysztof, Tahara Makoto, Pai Vasant R, Faivre Sandrine, Blajman Cesar R, Forastiere Arlene A, Stein Brian N, Oliner Kelly S, Pan Zhiying, Bach Bruce A, Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial, 10.1016/s1470-2045(13)70181-5
  3. León X., Hitt R., Constenla M., Rocca A., Stupp R., Kovács A.F., Amellal N., Bessa E.H., Bourhis J., A Retrospective Analysis of the Outcome of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Refractory to a Platinum-based Chemotherapy, 10.1016/j.clon.2005.02.014
  4. Stewart J. Simon W., Cohen Ezra E.W., Licitra Lisa, Van Herpen Carla M.L., Khorprasert Chonlakiet, Soulieres Denis, Vodvarka Pavel, Rischin Danny, Garin Avgust M., Hirsch Fred R., Varella-Garcia Marileila, Ghiorghiu Serban, Hargreaves Laura, Armour Alison, Speake Georgina, Swaisland Alan, Vokes Everett E., Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck, 10.1200/jco.2008.17.0530
  5. Machiels Jean-Pascal, Subramanian Somasundaram, Ruzsa Agnes, Repassy Gabor, Lifirenko Igor, Flygare Annika, Sørensen Per, Nielsen Tina, Lisby Steen, Clement Paul MJ, Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial, 10.1016/s1470-2045(11)70034-1
  6. Vermorken Jan. B., Herbst Roy S., Leon Xavier, Amellal Nadia, Baselga Jose, Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies, 10.1002/cncr.23442
  7. Brand T. M., Iida M., Stein A. P., Corrigan K. L., Braverman C. M., Luthar N., Toulany M., Gill P. S., Salgia R., Kimple R. J., Wheeler D. L., AXL Mediates Resistance to Cetuximab Therapy, 10.1158/0008-5472.can-14-0294
  8. Tinhofer I., Klinghammer K., Weichert W., Knodler M., Stenzinger A., Gauler T., Budach V., Keilholz U., Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment, 10.1158/1078-0432.ccr-10-3338
  9. Wheeler D L, Huang S, Kruser T J, Nechrebecki M M, Armstrong E A, Benavente S, Gondi V, Hsu K-T, Harari P M, Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members, 10.1038/onc.2008.19
  10. Pedersen M. W., Jacobsen H. J., Koefoed K., Hey A., Pyke C., Haurum J. S., Kragh M., Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy, 10.1158/0008-5472.can-09-1417
  11. Skartved N. J. O., Jacobsen H. J., Pedersen M. W., Jensen P. F., Sen J. W., Jorgensen T. K., Hey A., Kragh M., Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor, 10.1158/1078-0432.ccr-11-1209
  12. Dienstmann R, Tolcher AW, Papadopoulos KP et al (2011) Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors. J Clin Oncol 2011 ASCO Annual Meeting Abstracts. vol 29, No 15_suppl (May 20 Supplement):3089
  13. Dienstmann R, Tabernero J, Van Cutsem E et al (2013) Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC). J Clin Oncol 2013 ASCO Annual Meeting Abstracts. vol 31, No 15_suppl (May 20 Suppl):3551
  14. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), 10.1016/j.ejca.2008.10.026
  15. Duray Anaëlle, Descamps Géraldine, Bettonville Marie, Sirtaine Nicolas, Ernoux-Neufcoeur Perle, Guenin Samuel, Mouallif Mustapha, Depuydt Christophe E., Delvenne Philippe, Saussez Sven, High Prevalence of High-Risk Human Papillomavirus in Palatine Tonsils from Healthy Children and Adults, 10.1177/0194599811402944
  16. Iida Mari, Brand Toni M, Starr Megan M, Li Chunrong, Huppert Evan J, Luthar Neha, Pedersen Mikkel W, Horak Ivan D, Kragh Michael, Wheeler Deric L, Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab, 10.1593/neo.131584